FIELD: pharmaceuticals.
SUBSTANCE: compound of formula (I) or a veterinarily or pharmaceutically acceptable salt thereof or their use for the manufacture or as a drug for the treatment and/or control of D. immitis, H. contortus, T. colubriformis, A. viteae, or L. sigmodontis. In the general formula (I), n is equal to 1; X1 is CR1; X2 is CR2; X3 is CR3; X4 is CR4; X5 is CR5; and X6 is N; X1 is N; X2 is CR2; X3 is CR3; X4 is CR4; X5 is CR5; and X6 is N; X1 is N; X2 is CR2; X3 is N; X4 is CR4; X5 is CR5; and X6 is N; X1 is CR1; X2 is CR2; X3 is N; X4 is CR4; X5 is CR5; and X6 is N; X1 is CR1; X2 is CR2; X3 is CR3; X4 is CR4; X5 is CR5; and X6 is CR6; G is a group 
; Y1 is CR8R9; Y2 is selected from the group consisting of CR8R9 and O; Z1 is CR11; Z2 is CR11; Z3 is CR11; Z4 is CR11; R1 is hydrogen; R2 is hydrogen; R3 is hydrogen; R4 is selected from the group consisting of C1-C4alkyl, C3-C6cycloalkyl, C1-C4haloalkyl, -NH2, -NH(C1-C4alkyl), -N(C1-C4alkyl)2, -N(C1-C4alkyl)(C1-C4alkoxy), and a monocyclic heterocycle selected from the group consisting of 4-7-membered heterocycloalkyl containing one or two heteroatoms selected from a group consisting of nitrogen, oxygen and sulfur; the heterocycloalkyl ring in R4 is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, hydroxyl, oxo, and wherein each C1-C4alkyl and C3-C6cycloalkyl in R4 may be optionally substituted 1, 2 or 3 substituents independently selected from the group consisting of halogen, hydroxyl, -NH2 and cyano; R5, R6, R7, R8, R9, R11 are hydrogen; R12 is C1-C4haloalkyl; and Q is 6-membered aryl optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C1-C4alkyl and C1-C4haloalkyl ; M is O.
EFFECT: development of compounds for treatment and/or control of endoparasites D. immitis, H. contortus, T. colubriformis, A. viteae, or L. sigmodontis.
10 cl, 1 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC DERIVATIVES | 2019 |
|
RU2794894C2 |
| PESTICIDALLY ACTIVE POLYCYCLIC DERIVATIVES WITH SULFUR-CONTAINING SUBSTITUTES | 2015 |
|
RU2738359C2 |
| AZABICYCLIC AND DIAZEPINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS | 2018 |
|
RU2795521C2 |
| DELAYED-RELEASE DELIVERY SYSTEMS CONTAINING TRACELESS LINKERS | 2018 |
|
RU2772690C2 |
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
| SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | 2012 |
|
RU2569635C9 |
| IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
| HERBICIDAL SUBSTITUTED PYRIMIDINYLOXYBENZOLE COMPOUNDS | 2014 |
|
RU2703460C1 |
| MEDICINAL COMPOUNDS | 2014 |
|
RU2691105C1 |
| UREA-BASED COMPOUNDS AND COMPOSITIONS BASED ON THEM AS SMARCA2/BRM ATPASE INHIBITORS | 2019 |
|
RU2798462C2 |
